Abivax H1 EPS $(2.43) Misses $(1.08) Estimate, Sales $2.959M Beat $1.860M Estimate

Abivax reported a first-half loss of $(2.43) per share, missing the analyst estimate of $(1.08) by 125%. This represents a 65.31% increase in losses compared to $(1.47) per share from the same period last year. The company's sales reached $2.959 million, exceeding the $1.860 million estimate by 59.09%, but this reflects a 61.71% decrease from $7.727 million in the previous year.